¹¹C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy.

ABSTRACT:

Purpose

To assess the potential for ¹¹C-methionine PET (Met-PET) coregistered with volumetric magnetic resonance imaging (Met-PET/MR^CR) to inform clinical decision making in patients with poorly visualized or occult microprolactinomas and dopamine agonist intolerance or resistance.

Patients and methods

Thirteen patients with pituitary microprolactinomas, and who were intolerant (n = 11) or resistant (n = 2) to dopamine agonist therapy, were referred to our specialist pituitary centre for Met-PET/MR^CR between 2016 and 2020. All patients had persistent hyperprolactinemia and were being considered for surgical intervention, but standard clinical MRI had shown either no visible adenoma or equivocal appearances.

Results

In all 13 patients M

SUBMITTER: Bashari WA 

PROVIDER: S-EPMC9345820 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature